唑来膦酸治疗老年原发性骨质疏松症的临床安全性观察  

Clinical safety observation of zoledronic acid treatment for senile primary osteoporosis

作　　者：郝杰[1] 胡侦明[1] 张晓军[1] 江维[1] 沈皆亮[1] 

机构地区：[1]重庆医科大学附属第一医院骨科,重庆400016

出　　处：《中国骨质疏松杂志》2013年第1期61-63,共3页Chinese Journal of Osteoporosis

摘　　要：目的探讨临床应用唑来膦酸静脉滴注治疗老年原发性骨质疏松症的安全性和依从性。方法观察首次静脉滴注唑来膦酸治疗50例原发性骨质疏松症患者的一般情况和副反应,询问患者是否愿意接受第二次治疗。结果所有患者在滴注过程中均无严重不良反应发生,但24%患者在输注后3d内出现了急性一过性不良反应,包括发热、关节痛、肌痛、流感样症状、头痛等,绝大多数患者同意继续使用。结论唑来膦酸治疗原发性骨质疏松症安全性较高,依从性好,是一种较理想的治疗新选择,其疗效有待于长期随访。Objective To investigate the safety and compliance of zoledronic acid, which was clinically used through intravenous injection, for the treatment of senile primary osteoporosis. Methods A total of 50 patients with primary osteoporosis who were treated with zoledronie acid intravenously for the first-time were enrolled. General condition and adverse reaction of all the patients were observed. Their willing about whether to receive the 2nd treatment or not was inquired. Results None of 50 patients had severe adverse reaction during the process of intravenous injection, Whereas 24% patients had acute and temporary adverse reaction, including fever, joint pain, myosalgia, influenza-like symptom, and headache in the first 3 days after intravenously injection. Most patients agreed to use zoledronic acid for the treatment continually. Conclusion The safety of zoledronie acid for the dreatment of primary osteoporosis is high, and the compliance is good. The treatment is a new ideal choice, but the clinical effect needs long-term follow-up.

关 键 词：唑来膦酸 原发性骨质疏松 老年 双膦酸盐 

分 类 号：R961[医药卫生—药理学] R681[医药卫生—药学]